Current Document Type: HighlightsVideoPage MEDALIST Trial of Luspatercept to Treat Anemia - JADPRO

Watch More Highlights

Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses study findings that showed most patients with lower-risk myelodysplastic syndrome treated with luspatercept, a first-in-class erythroid maturation agent, achieved independence from red blood cell transfusions and/or hematologic improvement (Abstract 841).

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.